医薬品研究開発動向：2007年

Abstract

Utilising daily-updated data, plus an extensive new review of R&D investment, this essential report examines the research investment and drug pipelines for 39 leading companies.

Few issues occupy as much executive and analyst time as the productivity of the industry' s research and development effort. Many forecast the impending doom of the ethical industry as we know it, citing the imbalance of patent expiries against new product launches, the absence of any real recent blockbusters and the rise of generic competition and regulatory demands.

Fundamental questions need answers

• But what is the real situation in pharma R&D?
• What is the new product launch calendar looking like?
• What are the latest clinical trial results?
• What is the status, by development phase, of companies' R&D pipelines?
• Which companies are committing most investment to their R&D effort?

This report provides key information

Executives need current and independent information to answer these and similar questions. That is why Espicom Business Intelligence - the leading provider of pharmaceutical competitive intelligence - has published The Pharma R&D Fact Book 2007.

This essential report examines the research investment and drug pipelines for 39 leading companies from Abbott and Alcon to UCB and Wyeth. A complete list of companies in the report is provided below.

Utilising daily-updated data, plus an extensive review of R&D investment, the 600+ page report contains a wealth of essential information including:

• At-a-glance bullet point summaries of key business facts and events for each company.
• Extensive analysis of R&D investment, dating back to 1997 with forecasts to 2011.
• Analysis of investment by US, European and Japanese companies .
• Research ratios by company, region and 10-year change. Company-by-company graphs showing their performance against the industry average.
• R&D pipeline and graphs for each company showing the numbers of compounds in development by stage, split by novel compounds, new indications and new formulations.
• Extensive monographs of each company' s pipeline showing key data such as development status, clinical trial results, licensing and deals.

Table of Contents

Volume 1

Introduction

• The Cost of Developing a New Drug
• The Drug Development Process
• Regulatory Changes
• ..the situation in the US
• Post-regulation .. the Role of Watchdogs
• Generics
• The Way Forward
• Notes & Definitions
• Company Notes

DATA TABLES

• Exchange Rates (against US$)
• Country and Region of Domicile, Reporting Year-End, Currency and Revenues from Pharmaceutical Products
• Total Revenues by Company 1997-2011 (Local Currency)
• R&D Expenditure by Company 1997-2011 (Local Currency)
• Five Year Change in R&D Expenditure Ranked by Value 2002-2006
• (US$ million, at Constant 2002 Exchange Rates; Mean Change=72.5; SD=73.87)
• Five Year Change in R&D Expenditure Ranked by Percentage Change 2002-2006
• (US$ million, at Constant 2002 Exchange Rates; Mean Change=72.5; SD=73.87)
• Ten Year Change in R&D Expenditure 1997-2006
• (US$ million, at Constant 1997 Exchange Rates; Mean Change=205.6; SD=226.9)
• Predicted Change in R&D Expenditure Ranked by Value 2006-2011
• (US$ million, at Constant 2006 Exchange Rates)
• Predicted Change in R&D Expenditure Ranked by Percentage Change 2006-2011
• (US$ million, at Constant 2006 Exchange Rates)
• US Companies by R&D Expenditure by Company 2002-2006 (US$ million)
• R&D Expenditure for Top Ten US Companies
• European Companies by R&D Expenditure 2002-2006 (US$ million)
• R&D Expenditure for Top Ten European Companies
• Japanese Companies by R&D Expenditure 2002-2006 (US$ million)
• R&D Expenditure for Top Ten Japanese Companies
• Total R&D Expenditure for Featured Companies
• Research Ratio (%) by Company 1997-2011
• Five Year Change in R&D Ratio (%) Ranked by Value 2002-2006 (Mean Change=2.5; SD=5.84)
• Five Year Change in R&D Ratio (%) Ranked by Point Change 2002-2006 (Mean Change=2.5; SD=5.84)
• Ten Year Change in R&D Ratio (%) by Point Change 1997-2006 (Mean Change=1.4; SD=5.87)
• Predicted Change in R&D Ratio (%) by Value 2006-2011 (Mean Change=0.0)
• Predicted Change in R&D Ratio (%) by Point Change 2006-2011 (Mean Change=0.90)
• US Companies by Five Year Change in R&D Ratio (%) by Point Change 2002-2006 (Mean Change=2.2 SD=7.92)
• Research Ratios for Top Ten US Companies
• European Companies by Five Year Change in R&D Ratio (%) by Point Change 2002- 2006 (Mean Change=0.9; SD=2.49)
• Research Ratios for Top European Companies
• Japanese Companies by Five Year Change in R&D Ratio (%) by Point Change 2002-2006 (Mean Change=4.8; SD=2.54)
• Research Ratios for Top Ten Japanese Companies
• R&D Pipeline Summary Table 2007 - Products by Trial Phase

Abbott

• R&D PIPELINE
• INFLAMMATION
• ANTI-INFECTIVES
• NEUROSCIENCE
• VIROLOGY
• CARDIOVASCULAR
• ONCOLOGY
• GASTROINTESTINAL
• OTHERS

Alcon

• R&D PIPELINE
• OPHTHALMOLOGY
• OTIC

Allergan

• R&D PIPELINE
• NEUROSCIENCES
• OPTHTHALMOLOGY
• MEDICAL DERMATOLOGY
• OTHER

Amgen

• R&D PIPELINE
• HAEMATOLOGY
• IMMUNOLOGY
• INFLAMMATION
• ONCOLOGY
• OTHER

Astellas Pharma

• R&D PIPELINE
• CARDIOVASCULAR
• UROLOGY
• INFLAMMATION & IMMUNOLOGY
• GASTROINTESTINAL
• INFECTIOUS DISEASE
• CENTRAL NERVOUS SYSTEM
• METABOLIC
• BONE DISORDERS
• ONCOLOGY

AstraZeneca

• R&D PIPELINE
• GASTROINTESTINAL
• CARDIOVASCULAR
• NEUROSCIENCE
• CANCER
• RESPIRATORY AND INFLAMMATION
• INFECTION

Bayer

• R&D PIPELINE
• WOMEN' S HEALTHCARE
• HEMATOLOGY/CARDIOLOGY
• DIAGNOSTIC IMAGING
• SPECIALIZED THERAPEUTICS
• ONCOLOGY

Boehringer Ingelheim

• R&D PIPELINE
• RESPIRATORY
• CARDIOVASCULAR
• UROLOGY
• CENTRAL NERVOUS SYSTEM
• IMMUNOLOGY AND INFLAMMATION
• VIROLOGY
• ONCOLOGY
• METABOLIC

Bristol-Myers Squib

• R&D PIPELINE
• CARDIOVASCULAR AND METABOLIC DISEASES
• VIROLOGY
• NEUROSCIENCE
• ONCOLOGY
• IMMUNOLOGY
• OTHERS

Chugai Pharmaceutical

• R&D PIPLINE
• ONCOLOGY
• RENAL DISEASES
• TRANSPLANT, IMMUNOLOGY AND INFECTIOUS DISEASES
• BONE AND JOINT
• CARDIO/CEREBRO-VASCULAR
• OTHER

Daichi Sankyo

• R&D PIPELINE
• CARDIOVASCULAR
• METABOLISM
• INFECTION
• IMMUNITY AND ALLERGY
• BONE AND JOINTS
• CANCER
• OTHERS

Dainipon Sumitomo Pharma

• R&D PIPELINE
• CARDIOVASCULAR
• ONCOLOGY/INFECTION
• INFLAMMATION/ALLERGY
• CENTRAL NERVOUS SYSTEM
• DIABETES
• OTHER

Eisai

• R&D PIPELINE
• NEUROLOGY
• GASTROENTEROLOGY
• CARDIOVASCULAR AND RESPIRATORY
• METABOLIC
• DIAGNOSTICS
• ANTI-INFECTIVES
• ONCOLOGY
• OTHER

EliLily

• R&D PIPELINE
• NEUROSCIENCE
• ENDOCRINE DISEASES
• ONCOLOGY
• CARDIOVASCULAR
• ANTI-INFECTIVES
• OTHERS

Forest Laboratories

• R&D PIPELINE
• CENTRAL NERVOUS SYSTEM
• CARDIOVASCULAR
• OTHER

Gilead

• R&D PIPELINE
• ANTI-VIRAL
• OTHERS

GlaxoSmithKline

• R&D PIPELINE
• RESPIRATORY
• NEUROSCIENCES
• ANTIVIRALS
• ANTIBACTERIALS/ANTIMALARIALS
• METABOLIC
• VACCINES
• CARDIOVASCULAR
• UROGENITAL
• ONCOLOGY AND EMESIS
• GASTROINTESTINAL
• MUSCULOSKELETAL & INFLAMMATION

Volume 2

JOHNSON & JOHNSON

• R&D PIPELINE
• CENTRAL NERVOUS SYSTEM
• HAEMATOLOGY
• IMMUNOLOGY
• ANTI-INFECTIVE
• GASTROINTESTINAL
• REPRODUCTIVE HEALTH
• ONCOLOGY
• CARDIOVASCULAR
• OTHER

KYOWA HAKKO

• R&D PIPELINE
• ANTI-ALLERGY
• CENTRAL NERVOUS SYSTEM
• ANTICANCER
• GASTROINTESTINAL
• OTHERS

LUNDBECK

• R&D PIPELINE
• CENTRAL NERVOUS SYSTEM

MERCK KGAA

• R&D PIPELINE
• NEUROLOGY
• CARDIOMETABOLIC CARE
• METABOLISM
• REPRODUCTIVE HEALTH
• ONCOLOGY
• AUTOIMMUNE / INFLAMMATORY
• OTHER

MERCK & CO

• R&D PIPELINE
• CARDIOVASCULAR
• RESPIRATORY
• ANTI-INFLAMMATORY
• VACCINES & BIOLOGICALS
• ANTIBACTERIALS/ANTIFUNGALS
• OPHTHALMOLOGICAL
• UROLOGY
• NEUROLOGY
• METABOLIC
• ONCOLOGY
• HIV
• OTHERS

MITSUBISHI PHARMA

• R&D PIPELINE
• CIRCULATORY SYSTEM AND METABOLISM
• NEUROPSYCHIATRY
• RESPIRATORY SYSTEM AND IMMUNOLOGY
• ONCOLOGY AND HEPATOLOGY
• OTHER

NOVARTIS

• R&D PIPELINE
• CARDIOVASCULAR AND METABOLISM
• ONCOLOGY/HAEMATOLOGY
• NEUROSCIENCE
• ARTHRITIS/BONE
• GASTROINTESTINAL
• RESPIRATORY/DERMATOLOGY
• TRANSPLANTATION/IMMUNOLOGY
• INFECTIOUS DISEASES
• OPHTHALMICS

NOVO NORDISK

• R&D PIPELINE
• DIABETES CARE
• BIOPHARMACEUTICALS

NYCOMED

• R&D PIPELINE
• PAIN
• RESPIRATORY
• OTHERS

OTSUKA

• R&D PIPELINE
• CARDIOVASCULAR
• GASTROINTESTINAL
• CENTRAL NERVOUS SYSTEM
• ANTICANCER
• ANTI-INFECTIVE
• RESPIRATORY
• OTHERS

PFIZER

• R&D PIPELINE
• CARDIOVASCULAR / METABOLISM
• CENTRAL NERVOUS SYSTEM
• INFECTIOUS AND RESPIRATORY
• UROLOGY
• ARTHRITIS AND PAIN
• ONCOLOGY
• OPHTHALMOLOGY
• ENDOCRINE DISORDERS
• WOMEN' S HEALTHCARE
• OTHER

PROCTER & GAMBLE

• R&D PIPELINE
• MUSCUOLOSKELETAL
• GASTROINTESTINAL
• CARDIOVASCULAR

RECORDATI

• R&D PIPELINE
• CARDIOVASCULAR
• CENTRAL NERVOUS SYSTEM
• GASTROENTEROLOGY/UROLOGY
• RESPIRATORY
• ANTI-INFECTIVES
• OTHERS

ROCHE

• R&D PIPELINE
• ONCOLOGY
• VIROLOGY/INFECTIOUS DISEASES
• INFLAMMATORY, AUTOIMMUNE AND TRANSPLANTATION
• METABOLISM & BONE
• ANAEMIA
• CARDIOVASCULAR
• CENTRAL NERVOUS SYSTEM
• RESPIRATORY
• OPHTHALMOLOGY
• OTHERS

SANOFI-AVENTIS

• R&D PIPELINE
• CARDIOVASCULAR / THROMBOSIS
• ONCOLOGY
• CENTRAL NERVOUS SYSTEM
• METABOLISM / DIABETES
• VACCINES
• RESPIRATORY / ALLERGY
• ARTHRITIS / OSTEOPOROSIS
• GENITO-URINARY
• ANTI-INFECTIVE
• OTHER

SCHERING-PLOUGH

• R&D PIPELINE
• ALLERGY & RESPIRATORY
• ANTIVIRAL
• ANTI-INFLAMMATORY
• ONCOLOGY
• ANTI-INFECTIVES
• CARDIOVASCULAR
• OTHERS

SHIONOGI

• R&D PIPELINE
• INFECTIOUS DISEASES
• METABOLIC SYNDROME
• ANTICANCER
• NEUROLOGY
• ALLERGY
• CIRCULATORY SYSTEM
• OTHER

SOLVAY

• R&D PIPELINE
• CARDIOMETABOLICS
• WOMEN' S AND MEN' S HEALTH
• NEUROSCIENCE
• PANCREATIC ENZYMES
• INFLUENZA VACCINES
• OTHERS

TAKEDA

• R&D PIPELINE
• METABOLIC
• CARDIOVASCULAR
• GASTROINTESTINAL
• ANTICANCER
• MUSCULOSKELETAL
• CENTRAL NERVOUS SYSTEM
• OTHERS

TANABE

• R&D PIPELINE
• CARDIOVASCULAR AND RESPIRATORY SYSTEM
• CENTRAL AND PERIPHERAL NERVOUS SYSTEM
• IMMUNOLOGY AND INFLAMMATION
• OTHERS

UCB

• R&D PIPELINE
• CENTRAL NERVOUS SYSTEM
• IMMUNO-ALLERGOLOGY
• ONCOLOGY
• OTHERS

WYETH

• R&D PIPELINE
• NEUROSCIENCE
• GASTROENTEROLOGY
• VACCINES
• MUSCULOSKELETAL
• WOMEN' S HEALTHCARE / CONTRACEPTION
• ANTI-INFECTIVES
• IMMUNOLOGY
• ONCOLOGY
• CARDIOVASCULAR & METABOLIC DISORDERS
• OTHERS